These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 18396622

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC, Crommelin MA, Repelaer van Driel OJ, Tutein Nolthenius-Puylaert MC, Vreugdenhil G, Coebergh JW.
    Ned Tijdschr Geneeskd; 1998 Aug 01; 142(31):1772-8. PubMed ID: 9856143
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD.
    J Clin Oncol; 2005 Sep 01; 23(25):5973-82. PubMed ID: 16087950
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Sep 01; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.
    Clin Cancer Res; 2009 May 15; 15(10):3610-6. PubMed ID: 19401349
    [Abstract] [Full Text] [Related]

  • 35. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
    De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.
    Clin Cancer Res; 2005 Jul 01; 11(13):4741-8. PubMed ID: 16000569
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, Shen TZ, Hade EM, Young GS, Jarjoura D.
    J Clin Oncol; 2008 Jan 10; 26(2):253-7. PubMed ID: 18086800
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD.
    J Surg Res; 2007 Jul 10; 141(1):53-9. PubMed ID: 17574038
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.